Health Blueprint

Back to Longevity News

News summary

Obesity Week 2026 | Laekna Announces Poster Presentation on LAE124, an Internally Discovered Oral Small-Molecule Amylin Receptor Agonist

Source: PR Newswire • Published: 12 Nov 2026, 04:01

Summarized by Masters of Longevity from PR Newswire.

LAE124 reduced food intake and produced dose-dependent weight loss in DIO rats.

Obesity Week 2026 | Laekna Announces Poster Presentation on LAE124, an Internally Discovered Oral Small-Molecule Amylin Receptor Agonist
Key Takeaways
  • LAE124 is a dual amylin/calcitonin receptor agonist.
  • Daily oral dosing in rats produced robust weight reduction.
  • Findings are preclinical and do not prove human benefit.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.